Brief: Cytodyn Announces FDA Accepts Revised Rolling Review Timeline For Resubmission Of Its BLA
28/10/2021 05:45
Oct 28 (Reuters) - Cytodyn Inc CYDY.PK :
* CYTODYN ANNOUNCES FDA ACCEPTS REVISED ROLLING REVIEW
TIMELINE
FOR RESUBMISSION OF ITS BLA
* CYTODYN INC - MANAGEMENT EXPECTS NON-CLINICAL AND CMC
SECTIONS
OF BLA TO BE RESUBMITTED TO FDA IN NOVEMBER
Source text for Eikon: ID:nGNXbMNrDg
Further company coverage: CYDY.PK
((reuters.briefs@thomsonreuters.com;))
Recent news on Cytodyn
See all newsBrief: Cytodyn Appoints Robert E. Hoffman As Chief Executive Officer
Brief: Cytodyn Closes $17.5 Million Financing To Fund Continued Development Of Leronlimab
Brief: CytoDyn Inc Files For Offering Of Up To 120 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
Brief: Cytodyn Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer